Clinical Trials
24 trialsNF110
University of Alabama at Birmingham
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
Massachusetts General Hospital
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Massachusetts General Hospital
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Icotinib
Beijing Tiantan Hospital
A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)
NYU Langone Health
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
University of Alabama at Birmingham
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
NYU Langone Health
Effect of Implant Position on Magnetic Resonance Image Distortion
Manchester University NHS Foundation Trust
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
National Institutes of Health Clinical Center (CC)
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
National Cancer Institute (NCI)
Resiliency Training for Patients With NF2 Via Videoconferencing With Skype
Massachusetts General Hospital
Reliability of Functional Outcome Measures in Neurofibromatosis 2
Guy's and St Thomas' NHS Foundation Trust
NF2
University Hospital Tuebingen
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
NYU Langone Health
AFINF2
Assistance Publique - Hôpitaux de Paris
Endostatin
Beijing Tiantan Hospital
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
Massachusetts General Hospital
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
NYU Langone Health
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
FDA Office of Orphan Products Development
An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
FDA Office of Orphan Products Development